Direkt zum Inhalt
Merck
  • One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney, Australia.

One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney, Australia.

Sexual health (2013-09-14)
Phillip J Read, E Athena Limnios, Anna McNulty, David Whiley, Monica M Lahra
ZUSAMMENFASSUNG

Emerging antimicrobial resistance within Neisseria gonorrhoeae (NG) is a significant global public health threat. Detection and investigation of treatment failures is a crucial component of the World Health Organisation's response to this challenge. We report the cases of two homosexual men, both treated for pharyngeal NG with 500mg intramuscular ceftriaxone, in whom a test of cure 1 week after treatment showed persisting infection. Both men denied further sexual activity. In the first case, treatment failure was confirmed, since the isolates before and after treatment were identical by auxotype, antibiogram, multilocus sequence type (MLST) and multi-antigen sequence type (NG-MAST). In the second case, the MLSTs before and after treatment were identical, but NG-MAST results were similar but not indistinguishable. These cases underline the importance of test-of-cure and molecular investigations in identifying treatment failure, but also highlight the complexity of distinguishing treatment failure from reinfection when relying on highly variable molecular targets that may be subject to drug pressure.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ceftriaxon Dinatriumsalz Hemi(heptahydrat), third-generation cephalosporin antibiotic
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge
Ceftriaxon-Natrium, European Pharmacopoeia (EP) Reference Standard
SKU
Packungsgröße
Verfügbarkeit
Preis
Menge